Skip to content
DraconiticResearch
Search Sources API
197,768 studies31 sourcesUpdated 26 min ago
Peer-reviewedCC BY 4.0Journal of Clinical Ultrasound

Analysis of High‐Risk Factors for Failure of Bleeding Control in Enhanced Myometrial Vascularity Treated With Uterine Artery Embolization

  • Linhua Zhu1
  • Yongfang Yue1
  • Lili Cao2
  1. 1Women's Hospital School of Medicine, Zhejiang University Hangzhou China
  2. 2Hangzhou Linping District Maternal & Child Health Care Hospital Hangzhou China
Read full textDOICite

Abstract

Purpose: Enhanced myometrial vascularity (EMV) is a condition frequently linked to abnormal uterine bleeding during pregnancy, leading to significant morbidity, including severe bleeding and anemia. It poses a considerable economic burden on healthcare systems. This study aims to explore the factors influencing treatment outcomes in patients undergoing uterine artery embolization (UAE) for bleeding from EMV.

Methods: A retrospective analysis was performed on 110 patients treated with UAE in the Women's Hospital, Zhejiang University School of Medicine, yielding a success rate of 94 out of 110 cases. Sixteen patients with treatment failure were included in the study group, and 94 successfully treated patients were included in the control group.

Results: Key findings revealed that patients in the study group were younger, presented with larger uterine EMV diameters, had longer intervals since their last uterine surgery, and more frequently exhibited uterine fundal involvement (p < 0.05). Binary logistic regression analysis identified diameter of uterine EMV (OR = 3.23, 95% CI: 1.59–8.51, p < 0.05) and uterine fundal involvement (OR = 74.03, 95% CI: 7.88–697.40, p < 0.05) as significant risk factors for treatment failure. Postoperative follow‐up demonstrated that the treatment failure group had significantly prolonged bleeding times and a higher incidence of unchanged or enlarged malformations compared with the successful treatment group (p < 0.05).

Conclusion: These findings suggest that EMV size and uterine fundal involvement are critical determinants of UAE treatment failure, providing important evidence for clinical risk assessment and future research on the management of EMV‐related bleeding.

Related

  1. Ultrasound parameters for predicting high bleeding risk and efficacy of uterine artery embolization in gestational sac-type cesarean scar pregnancy: a retrospective single-center study
    Quanlin Ren, Tian Tian, Hong Luo
    Quantitative imaging in medicine and surgeryPeer-reviewedCC BY-NC-NDFull textMedical imaging & radiologyEurope PMC
  2. Factors associated with treatment response to microwave ablation of benign thyroid nodules: a retrospective single-center study of nodule composition and vascularity
    Mehmet Demir, Feza Demir, Cetin Murat Altay +2
    Frontiers in EndocrinologyPeer-reviewedCC BY 4.0Endocrinology & metabolismCrossref
  3. Factors influencing future liver remnant hypertrophy after portal vein embolization: a mini review.
    Yuxuan Lu, Hangcheng Liu, Boyang Wu +7
    Frontiers in surgeryPeer-reviewedCC BYFull textSurgery & anaesthesiaEurope PMCPMC
  4. Risk factors for recurrent variceal bleeding after TIPS in cirrhotic patients with esophagogastric variceal hemorrhage: a single-center retrospective study
    Zhiliang Chen, Yi Gou, Wenke Li +3
    Frontiers in medicinePeer-reviewedCC BYFull textGeneral medicineEurope PMC
  5. Human myometrial cell fate under chronic oxidative stress for leiomyomagenesis
    Jian-Jun Wei, Matthew John Schipma, Yue Feng +3
    Scientific ReportsPeer-reviewedCC BY-NC-ND 4.0Full textObstetrics, gynaecology & paediatricsCrossref

Cite

BibTeXRIS
BibTeX
@article{zhu2026analysis,
  title = {{Analysis of High‐Risk Factors for Failure of Bleeding Control in Enhanced Myometrial Vascularity Treated With Uterine Artery Embolization}},
  author = {Linhua Zhu and Yongfang Yue and Lili Cao},
  journal = {Journal of Clinical Ultrasound},
  year = {2026},
  month = jul,
  doi = {10.1002/jcu.70341},
  url = {https://doi.org/10.1002/jcu.70341},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - Analysis of High‐Risk Factors for Failure of Bleeding Control in Enhanced Myometrial Vascularity Treated With Uterine Artery Embolization
AU  - Linhua Zhu
AU  - Yongfang Yue
AU  - Lili Cao
PY  - 2026
DA  - 2026/07/14
JO  - Journal of Clinical Ultrasound
DO  - 10.1002/jcu.70341
UR  - https://doi.org/10.1002/jcu.70341
AB  - Purpose: Enhanced myometrial vascularity (EMV) is a condition frequently linked to abnormal uterine bleeding during pregnancy, leading to significant morbidity, including severe bleeding and anemia. It poses a considerable economic burden on healthcare systems. This study aims to explore the factors influencing treatment outcomes in patients undergoing uterine artery embolization (UAE) for bleeding from EMV.  Methods: A retrospective analysis was performed on 110 patients treated with UAE in the Women's Hospital, Zhejiang University School of Medicine, yielding a success rate of 94 out of 110 cases. Sixteen patients with treatment failure were included in the study group, and 94 successfully treated patients were included in the control group.  Results: Key findings revealed that patients in the study group were younger, presented with larger uterine EMV diameters, had longer intervals since their last uterine surgery, and more frequently exhibited uterine fundal involvement (p < 0.05). Binary logistic regression analysis identified diameter of uterine EMV (OR = 3.23, 95% CI: 1.59–8.51, p < 0.05) and uterine fundal involvement (OR = 74.03, 95% CI: 7.88–697.40, p < 0.05) as significant risk factors for treatment failure. Postoperative follow‐up demonstrated that the treatment failure group had significantly prolonged bleeding times and a higher incidence of unchanged or enlarged malformations compared with the successful treatment group (p < 0.05).  Conclusion: These findings suggest that EMV size and uterine fundal involvement are critical determinants of UAE treatment failure, providing important evidence for clinical risk assessment and future research on the management of EMV‐related bleeding.
SN  - 0091-2751
SN  - 1097-0096
ER  -